CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Migraine is a complex chronic neurovascular disorder characterised by recurrent moderate to severe headaches with a number of associated symptoms. Both genetic and environmental factors are known to play a part in the disorder.
The neuropeptide calcitonin gene-related peptide (CGRP) is a very potent vasodilator which plays a major role in migraine pathophysiology. It was first identified over 30 years ago and is found as two isoforms, one in the peripheral nervous and central nervous system (α-CGRP) and the other (β-CGRP) mainly in the enteric nervous system surrounding the intestines.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
